TC Biopharm announces first patient completes full dose regimen in ACHIEVE trial

TC BioPharm announced that the first patient has completed the full dose regimen in the ACHIEVE Phase 2b trial ongoing in the UK with no drug related Adverse Events seen in any of the re start patients. The ACHIEVE UK clinical trial is an open-label, phase II study designed to evaluate the efficacy and effectiveness of TCB008 in patients with AML or MDS/AML, with either refractory or relapsed disease. Patients are eligible to receive up to 4 total doses of TCB under the ACHIEVE protocol. One patient in Cohort A has successfully completed the full dosing regimen having received all 4 doses. Preliminary safety data indicate the 5mL dose of TCB008 is well tolerated, with no TCB008-related Adverse Events. These data outputs are indicative of TCB008’s safety profile, in support of the ACHIEVE study safety objectives and endpoints. It’s expected that a further three patients will have received their 4th and final dose by the end of September. TC Biopharm expects to be able to announce a full data set in the first half of 2025 inclusive of primary and secondary endpoints.